Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT04268498 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT04268498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04268498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 11, 2020
Completion date
February 1, 2027
Enrollment
310 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma